Denali Therapeutics Inc. DNLI initiated dosing in a global mid-stage study, BEACON, on BIIB122 (DNL151). BIIB122, an ...

Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...

BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.

Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...

BEACON study is a phase IIa trial evaluating the company's investigational drug BIIB122 (DNL151), a selective LRRK2 inhibitor, for Parkinson's disease linked to LRRK2 mutations (LRRK2-PD).

DOVER, Del., Nov. 26, 2024 /PRNewswire/ -- Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 inhibitor developed as a potential ...

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LRRK2 inhibition is a potential therapeutic approach that may slow progression of Parkinson’s disease by targeting underlying lysosomal dysfunction implicated in this disease. The Phase 2a study ...

LRRK2 inhibition is a potential therapeutic approach that may slow progression of Parkinson’s disease by targeting underlying lysosomal dysfunction implicated in this disease. The Phase 2a study ...